Promimic ABOMXSTO: PRO

PRO: Record sales and robust growth, with new clinical approvals fueling future expansion

· Issued by Promimic AB

Record quarterly sales and 48% rolling 12-month growth driven by new product approvals and license deals. Cash flow remains negative, but strong market trends and new technologies support continued expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Promimic AB on 6ix

Later from Promimic

All Promimic news releases